TRP Channels in Brain Tumors.
TRP channel
brain tumor
glioblastoma
glioma
ion channel
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
10
2020
accepted:
17
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Malignant glioma including glioblastoma (GBM) is the most common group of primary brain tumors. Despite standard optimized treatment consisting of extensive resection followed by radiotherapy/concomitant and adjuvant therapy, GBM remains one of the most aggressive human cancers. GBM is a typical example of intra-heterogeneity modeled by different micro-environmental situations, one of the main causes of resistance to conventional treatments. The resistance to treatment is associated with angiogenesis, hypoxic and necrotic tumor areas while heterogeneity would accumulate during glioma cell invasion, supporting recurrence. These complex mechanisms require a focus on potential new molecular actors to consider new treatment options for gliomas. Among emerging and underexplored targets, transient receptor potential (TRP) channels belonging to a superfamily of non-selective cation channels which play critical roles in the responses to a number of external stimuli from the external environment were found to be related to cancer development, including glioma. Here, we discuss the potential as biological markers of diagnosis and prognosis of TRPC6, TRPM8, TRPV4, or TRPV1/V2 being associated with glioma patient overall survival. TRPs-inducing common or distinct mechanisms associated with their Ca
Identifiants
pubmed: 33928077
doi: 10.3389/fcell.2021.617801
pmc: PMC8076903
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
617801Informations de copyright
Copyright © 2021 Chinigò, Castel, Chever and Gkika.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cell Biol. 2015 Jan 5;208(1):89-107
pubmed: 25559186
Cancer Res. 2010 Jan 1;70(1):418-27
pubmed: 20028870
Cancers (Basel). 2019 Jul 08;11(7):
pubmed: 31288452
Cancers (Basel). 2019 Apr 12;11(4):
pubmed: 31013784
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
J Neurol Sci. 2008 Jul 15;270(1-2):152-8
pubmed: 18442831
Dev Cell. 2019 Jun 3;49(5):681-696.e6
pubmed: 31006651
Cell. 2002 Mar 8;108(5):705-15
pubmed: 11893340
Pharmacol Rev. 2015;67(1):36-73
pubmed: 25361914
J Neurophysiol. 1998 May;79(5):2782-93
pubmed: 9582244
Stem Cells. 2008 Nov;26(11):2945-54
pubmed: 18757298
Cold Spring Harb Perspect Biol. 2010 Oct;2(10):a003962
pubmed: 20861159
EMBO J. 2015 Apr 1;34(7):856-80
pubmed: 25712477
Nat Rev Mol Cell Biol. 2004 Oct;5(10):827-35
pubmed: 15459663
Cell Death Dis. 2019 Sep 9;10(9):652
pubmed: 31501416
Biol Cell. 2004 Sep;96(7):479-98
pubmed: 15380615
Tumour Biol. 2015 Dec;36(12):9209-13
pubmed: 26088448
Clin Cancer Res. 1995 Feb;1(2):207-14
pubmed: 9815975
Oncotarget. 2016 Jun 14;7(24):36168-36184
pubmed: 27102434
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51
pubmed: 11070094
Front Cell Neurosci. 2017 Dec 20;11:413
pubmed: 29326557
Folia Neuropathol. 2012;50(4):301-21
pubmed: 23319187
Adv Biol Regul. 2015 Jan;57:130-46
pubmed: 25465296
J Clin Invest. 2007 Jun;117(6):1647-57
pubmed: 17510704
Gene. 2015 Jan 25;555(2):194-202
pubmed: 25445271
Cell Mol Neurobiol. 2020 Jul;40(5):813-828
pubmed: 31845161
Elife. 2018 Sep 21;7:
pubmed: 30239332
Int J Mol Sci. 2018 Apr 08;19(4):
pubmed: 29642503
Oncotarget. 2016 Jul 12;7(28):43654-43668
pubmed: 27248469
Glia. 2010 Aug;58(10):1145-56
pubmed: 20544850
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19266-19275
pubmed: 32703809
Front Physiol. 2013 Nov 05;4:311
pubmed: 24204345
Stem Cell Rev Rep. 2011 Jun;7(2):292-306
pubmed: 21103958
Oncol Rep. 2017 Sep;38(3):1543-1550
pubmed: 28714015
Front Pharmacol. 2019 Oct 15;10:1198
pubmed: 31680972
Oncogenesis. 2017 May 22;6(5):e338
pubmed: 28530703
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Natl Cancer Inst. 2010 Jul 21;102(14):1052-68
pubmed: 20554944
Int Immunopharmacol. 2006 Jan;6(1):90-9
pubmed: 16332517
J Neurochem. 2011 Nov;119(3):474-85
pubmed: 21955047
Nat Neurosci. 2008 Jul;11(7):741-3
pubmed: 18516035
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Mol Med Rep. 2016 Jan;13(1):433-40
pubmed: 26718613
Int J Cancer. 2012 Oct 1;131(7):E1067-77
pubmed: 22492283
J Neurooncol. 2004 Nov;70(2):217-28
pubmed: 15674479
Oncotarget. 2016 Dec 6;7(49):81541-81554
pubmed: 27829230
Cell Signal. 2014 Dec;26(12):2773-81
pubmed: 25192910
Radiother Oncol. 2011 Oct;101(1):122-6
pubmed: 21704404
J Neurophysiol. 2001 Feb;85(2):790-803
pubmed: 11160513
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cell Calcium. 2011 Sep;50(3):279-87
pubmed: 21616534
Mol Cancer Ther. 2015 Oct;14(10):2215-27
pubmed: 26206334
Mol Pharm. 2019 Mar 4;16(3):1312-1326
pubmed: 30721081
Curr Opin Neurol. 2009 Dec;22(6):657-64
pubmed: 19770658
ISRN Neurol. 2011;2011:590249
pubmed: 22389824
Nat Commun. 2016 Jun 30;7:12109
pubmed: 27357649
Neurotox Res. 2019 May;35(4):797-808
pubmed: 30796690
J Neurochem. 2008 Nov;107(3):589-601
pubmed: 18691387
Sci Rep. 2019 May 28;9(1):7926
pubmed: 31138874
Cell Prolif. 2008 Feb;41(1):98-121
pubmed: 18211288
Oncol Lett. 2018 Jun;15(6):9777-9785
pubmed: 29928352
Cancer Res. 2013 Jan 15;73(2):990-9
pubmed: 23204229
Biochim Biophys Acta. 2009 Jun;1793(6):953-8
pubmed: 19103233
Carcinogenesis. 2010 May;31(5):794-803
pubmed: 20093382
Cell Mol Neurobiol. 2013 May;33(4):575-85
pubmed: 23529532
J Pathol. 2008 Aug;215(4):369-76
pubmed: 18523971
Cell Signal. 2016 Mar;28(3):136-147
pubmed: 26689735
Cancer Res. 2006 Aug 15;66(16):7843-8
pubmed: 16912155
Oncogene. 2010 Aug 12;29(32):4611-6
pubmed: 20531306
Cancers (Basel). 2018 Dec 05;10(12):
pubmed: 30563098
Biomed Pharmacother. 2019 Mar;111:292-304
pubmed: 30590317
Oncotarget. 2016 Mar 22;7(12):14259-78
pubmed: 26893360
J Cell Sci. 2008 Jul 15;121(Pt 14):2301-7
pubmed: 18559891
Oncol Rep. 2019 Oct;42(4):1517-1526
pubmed: 31524272
Neuro Oncol. 2017 Nov 29;19(12):1599-1606
pubmed: 28541485
J Recept Signal Transduct Res. 2012 Jun;32(3):134-41
pubmed: 22475023
Biochim Biophys Acta. 2007 Aug;1772(8):937-46
pubmed: 17616360
J Cell Physiol. 2011 Jul;226(7):1879-88
pubmed: 21506118
Nat Clin Pract Neurol. 2006 Sep;2(9):494-503; quiz 1 p following 516
pubmed: 16932614
Science. 2016 Jun 17;352(6292):1413-6
pubmed: 27313038
J Cell Physiol. 2009 May;219(2):344-53
pubmed: 19117012
Biochem Biophys Res Commun. 2018 Sep 5;503(2):876-881
pubmed: 29928875
Front Pharmacol. 2018 Nov 13;9:1234
pubmed: 30483120
J Biol Chem. 2007 Mar 16;282(11):7833-43
pubmed: 17197445
Brain Pathol. 2005 Oct;15(4):297-310
pubmed: 16389942
Glia. 2007 Dec;55(16):1668-79
pubmed: 17876807
Neuron Glia Biol. 2006 Feb;2(1):39-49
pubmed: 16520829
Science. 1995 Mar 10;267(5203):1456-62
pubmed: 7878464
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
Tumour Biol. 2015 Feb;36(2):967-72
pubmed: 25315188
Front Oncol. 2019 Dec 17;9:1413
pubmed: 31921670
Nat Commun. 2014 Jun 19;5:4196
pubmed: 24943270
Oncotarget. 2015 Jul 10;6(19):17221-36
pubmed: 25980497
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):259-67
pubmed: 15623782
Mol Cell Biochem. 2015 Oct;408(1-2):283-93
pubmed: 26160280
J Cell Biol. 2017 Jul 3;216(7):2107-2130
pubmed: 28550110
Nat Struct Mol Biol. 2019 Jan;26(1):40-49
pubmed: 30598551
Mol Biotechnol. 2006 Mar;32(3):227-48
pubmed: 16632889
J Clin Oncol. 2003 Apr 15;21(8):1624-36
pubmed: 12697889
Anticancer Res. 2007 Nov-Dec;27(6B):3987-92
pubmed: 18225560
Cancer. 2008 Sep 1;113(5):1032-42
pubmed: 18618497
Cancer Cell. 2018 Jun 11;33(6):985-1003.e7
pubmed: 29805077
Life Sci. 2013 Mar 12;92(4-5):317-24
pubmed: 23333822
Endocr Relat Cancer. 2005 Jun;12(2):367-82
pubmed: 15947109
J Neurochem. 2007 Aug;102(3):977-90
pubmed: 17442041
Arch Pathol Lab Med. 2007 Mar;131(3):397-406
pubmed: 17516742
Sci Signal. 2015 Jan 06;8(358):ra2
pubmed: 25564678
Endocr Metab Immune Disord Drug Targets. 2011 Mar;11(1):54-67
pubmed: 21348820
Nat Med. 2012 Aug;18(8):1232-8
pubmed: 22820645
Anticancer Agents Med Chem. 2016;16(4):490-500
pubmed: 26286659
Int J Cancer. 2015 Oct 15;137(8):1855-69
pubmed: 25903924
Curr Protein Pept Sci. 2014;15(7):732-7
pubmed: 25001513
Annu Rev Biochem. 2007;76:387-417
pubmed: 17579562
Autophagy. 2016 Oct 2;12(10):1954-1955
pubmed: 27485905
Neuro Oncol. 2010 Oct;12(10):1024-33
pubmed: 20627895
Front Neurosci. 2017 Feb 16;11:78
pubmed: 28261054
J Recept Signal Transduct Res. 2017 Feb;37(1):84-93
pubmed: 27055401
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Oncotarget. 2017 Sep 30;8(56):95896-95913
pubmed: 29221175
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Carcinogenesis. 2013 Jan;34(1):48-57
pubmed: 23079154
FASEB J. 2020 Jun;34(6):7483-7499
pubmed: 32277850
Lab Invest. 2018 Aug;98(8):989-998
pubmed: 29884911
Biochem Biophys Res Commun. 1997 Jun 27;235(3):743-7
pubmed: 9207232
Am J Physiol Cell Physiol. 2011 Sep;301(3):C541-9
pubmed: 21543740
Toxicol Appl Pharmacol. 2002 Jul 1;182(1):84-90
pubmed: 12127266
Microcirculation. 2017 Apr;24(3):
pubmed: 27809396
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Neurosci. 2001 Oct 1;21(19):7674-83
pubmed: 11567057
J Biomed Sci. 2009 Sep 24;16:90
pubmed: 19778436
Oncotarget. 2018 Apr 6;9(26):18400-18409
pubmed: 29719613
Cell Calcium. 2016 Dec;60(6):373-383
pubmed: 27638096
Biochem Biophys Res Commun. 2008 Jul 18;372(1):210-5
pubmed: 18485891